Skip to main content

Table 3 Deterministic, sensitivity and threshold results of the model for [68Ga]Ga-PSMA-11 PET/CT versus standard of care

From: Cost-effectiveness of the implementation of [68Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging

  Incremental cost (€) Incremental quality of life (QALY) ICER (€/QALY) Life years (years) Net Monetary Benefit* Incremental treatment cost (€) ** Incremental treatment quality of life (QALY) **
Standard of care (ePLND)*** € 35,659 10.271   15.25   €15,586 − 0.07
Strategy
PSMA PET/CT ([68Ga]Ga-PSMA-11 PET/CT) − € 674  − 0.011 €58,825 - 0.02 − € 243 − € 757  + 0.006
Threshold analysis
N1ext by [68Ga]Ga-PSMA-11 PET/CT (FP) = 0.8% − € 631 0.0003 Dominant − 0.005 € 654 − € 656  + 0.005
ePLND disutility = 0.052 − € 674 0.0002 Dominant − 0.018 € 694 − € 757  + 0.018
  1. *Net monetary benefit was calculated using a willingness to pay of €80,000 per QALY, for both increase and decrease of quality of life. ePLND extended pelvic lymph node dissection, FP false positive, ICER Incremental cost-effectiveness ratio, IKNL  the Netherlands Comprehensive Cancer Organisation, PET/CT  positron emission tomography/computed tomography, PSMA  prostate specific membrane antigen, QALY quality-adjusted life years.
  2. **Results from the decision table for treatment costs and effects
  3. ***For standard of care, the absolute costs and effects are shown